Welcome to our dedicated page for Statera Biopharma news (Ticker: STAB), a resource for investors and traders seeking the latest updates and insights on Statera Biopharma stock.
Overview of Statera Biopharma Inc.
Statera Biopharma Inc. (NASDAQ: STAB) is a biotechnology company dedicated to advancing immune health through innovative therapeutic solutions. The company’s core mission is to leverage the complex, pleiotropic effects of its drug candidates to restore immune balance, resolve disease, and achieve homeostasis. By focusing on the development of safe and effective treatments that act as natural analogs, Statera Biopharma aims to address a wide range of immune-related conditions, including autoimmune disorders, cancer, and infectious diseases.
Core Business Areas
At the heart of Statera Biopharma’s operations is its commitment to restoring immune health. The company’s drug development pipeline is built around therapies designed to work in a paracrine fashion, meaning they mimic natural biological signaling to promote healing and balance within the immune system. This approach allows Statera to target complex diseases with a holistic methodology, addressing underlying immune dysfunction rather than merely alleviating symptoms.
Market Position and Differentiation
Statera Biopharma operates within the competitive and rapidly evolving biopharmaceutical industry. Its emphasis on pleiotropic mechanisms—where a single therapeutic agent has multiple beneficial effects—sets it apart from traditional drug development strategies. By focusing on drugs that act as trans-activators of immune pathways, the company positions itself as a pioneer in immune health restoration. This unique approach not only differentiates Statera from competitors but also aligns with the growing demand for therapies that address the root causes of immune-related diseases.
Therapeutic Focus and Product Development
The company’s therapeutic focus spans several high-impact areas, including oncology, autoimmune diseases, and infectious diseases. Its pipeline is designed to address unmet medical needs by developing treatments that are both effective and safe. By leveraging its expertise in immune modulation, Statera Biopharma aims to create therapies that provide long-term benefits without significant side effects, a critical factor in patient adherence and treatment success.
Industry Context and Challenges
Statera Biopharma operates in a sector characterized by intense competition, rigorous regulatory requirements, and high R&D costs. Success in this industry often hinges on a company’s ability to innovate, secure intellectual property, and navigate clinical trials efficiently. Statera’s focus on immune health restoration positions it within a niche market that is gaining increasing attention due to the rising prevalence of immune-related diseases globally. However, the company must continuously adapt to industry dynamics and advancements in biotechnology to maintain its competitive edge.
Commitment to Innovation
Innovation is a cornerstone of Statera Biopharma’s business strategy. By embracing the concept of natural analogs and leveraging cutting-edge research, the company aims to develop therapies that not only treat but also transform the way immune-related diseases are managed. This commitment to innovation underscores Statera’s role as a forward-thinking player in the biopharmaceutical industry.
Conclusion
Statera Biopharma Inc. is a biotechnology company with a clear focus on restoring immune health through innovative therapeutic approaches. By leveraging the pleiotropic effects of its drug candidates and emphasizing safety and efficacy, the company addresses significant unmet medical needs in oncology, autoimmune diseases, and infectious diseases. Its unique approach to immune modulation positions it as a distinctive player in the biopharmaceutical industry, offering a compelling value proposition for patients, healthcare providers, and stakeholders.
Statera Biopharma (NASDAQ: STAB) announced a public offering of units consisting of common stock and warrants, correcting previous deal terms. The offering is underwritten by EF Hutton and registered under Form S-3 with the SEC. Each unit includes one year and five-year warrants. The preliminary prospectus supplement will be filed today. This offering aims to secure funds for advancing clinical programs targeting autoimmune diseases, cancers, and COVID-19. The company focuses on immune restoration therapies and holds a diverse platform of toll-like receptor agonists.
Statera Biopharma (NASDAQ: STAB) has initiated an underwritten public offering of units consisting of common stock and warrants. The offering is conducted under a shelf registration statement effective since May 29, 2020, with EF Hutton serving as the sole manager. The units include pre-funded options to purchase additional shares. The preliminary prospectus will be filed with the SEC, providing detailed terms of the offering. The press release emphasizes that this announcement does not constitute an offer to sell securities in jurisdictions where it would be illegal.
Statera Biopharma (NASDAQ: STAB) announced revised unaudited financial results for FY 2021, reporting revenues of $1,487,036, a 100% increase from 2020, driven by the acquisition of ImQuest Life Sciences. Operating costs surged to $31,587,009, up 191%, primarily due to research and development and general and administrative expenses. The company recorded a significant other expense of $68,667,633, largely from an expected goodwill impairment of $64,338,810. Despite challenges, Statera expects to report positive shareholders' equity.
Statera Biopharma (Nasdaq: STAB) is advancing its research on STAT-200 to enhance its immune modulation capabilities beyond opioid receptors, aiming to treat various inflammatory diseases. The company’s computational collaboration with MolSoft has led to the identification of hundreds of promising new drug compositions, with three currently undergoing synthesis for biologic validation. Statera, through its recent acquisition of ImQuest, plans to validate key compositions for safety and efficacy in treating multiple indications, tapping into the full potential of its proprietary platform.
Statera Biopharma (Nasdaq: STAB) has submitted a pilot study protocol to the FDA for STAT-205, targeting post-acute COVID-19. This critical milestone aims to explore STAT-205's efficacy in reducing fatigue and improving cognition in patients suffering from long COVID, with 84 patients expected to participate. Preliminary data suggests that STAT-205 may effectively combat SARS-CoV-2 progression. Statera is also conducting a Phase 1 trial of STAT-205 for treating mild COVID-19, projecting topline results in Q4.
Statera Biopharma (Nasdaq: STAB) has submitted a pilot study protocol to the FDA for its STAT-205 treatment, aimed at addressing post-acute COVID-19 syndrome, commonly known as long COVID. This Phase 1 clinical trial will evaluate the safety and efficacy of STAT-205 in reducing fatigue and improving cognitive function in approximately 84 participants. Preliminary in vitro data indicates the drug may slow the progression of the SARS-CoV-2 virus. The trial is a critical step in developing therapies for the significant health challenges posed by long COVID.
Statera Biopharma (NASDAQ: STAB) announced that Dr. Satish Chandran will join its Board of Directors as of February 24, 2022. Dr. Chandran, a seasoned biotechnology leader with over 30 years of experience, has held key roles at various biopharmaceutical companies. He replaces Steve Barbarick, who resigned from the board but will remain as an advisor. The company emphasizes its focus on advancing clinical milestones in immune therapies targeting conditions such as Crohn's disease and SARS-CoV-2 infections.
Statera Biopharma (NASDAQ: STAB) reported preliminary revenue of $1,487,036 for FY 2021, a 100% increase from 2020, attributed to the acquisition of ImQuest Life Sciences. However, operating costs surged 191% to $31,587,009, primarily due to increased R&D and administrative expenses. The net loss reached $34,892,762, a 189% rise from the previous year. The company anticipates significant clinical developments in 2022, including the submission of FDA protocols for their drug candidates.
Statera Biopharma announced that it has received approval from the Central Institutional Review Board to conduct a Phase 3 clinical trial for its drug STAT-201, aimed at treating pediatric Crohn’s Disease. The trial, set to begin in Q2 2022, will assess the safety and efficacy of STAT-201 in patients aged 12 to 17, with around 165 participants expected. Previous Phase 2 results showed a 67% remission rate without serious adverse events. The FDA has granted STAT-201 orphan drug designation for treating Crohn’s in pediatric patients, highlighting its potential in a growing patient demographic.
Statera Biopharma (NASDAQ: STAB) has successfully closed a registered direct offering, raising $2.0 million by selling approximately 2.0 million shares of its common stock along with warrants. Each warrant, exercisable at $1.00 per share and valid for five years, accompanies a share sold at the same price. The funds raised will support general corporate purposes, including critical studies for pediatric Crohn’s disease and acute COVID-19. EF Hutton was the sole placement agent for this offering.
FAQ
What is the current stock price of Statera Biopharma (STAB)?
What is the market cap of Statera Biopharma (STAB)?
What does Statera Biopharma Inc. specialize in?
What are the core therapeutic areas of Statera Biopharma?
How does Statera Biopharma differentiate itself from competitors?
What challenges does Statera Biopharma face in its industry?
What is the significance of pleiotropic effects in Statera Biopharma’s therapies?
